ABIVAX Société Anonyme (NASDAQ:ABVX) Receives $38.67 Average Target Price from Brokerages

Shares of ABIVAX Société Anonyme (NASDAQ:ABVX) have been given a consensus rating of “Buy” by the seven research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $38.67.

A number of research analysts have issued reports on ABVX shares. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. JMP Securities assumed coverage on shares of ABIVAX Société Anonyme in a research report on Wednesday, December 4th. They set an “outperform” rating and a $33.00 price target for the company.

ABIVAX Société Anonyme Stock Up 2.2 %

ABVX stock opened at $7.45 on Friday. The business has a 50 day moving average of $8.75 and a 200-day moving average of $10.67. ABIVAX Société Anonyme has a 12-month low of $6.53 and a 12-month high of $17.02.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Several institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC bought a new position in shares of ABIVAX Société Anonyme in the fourth quarter worth $29,000. Point72 Asset Management L.P. grew its holdings in ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares in the last quarter. Walleye Capital LLC increased its position in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after buying an additional 80,807 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares in the last quarter. Finally, abrdn plc boosted its position in shares of ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after acquiring an additional 198,225 shares during the period. Hedge funds and other institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.